Literature DB >> 9628087

Case study: caudate glutamatergic changes with paroxetine therapy for pediatric obsessive-compulsive disorder.

G J Moore1, F P MacMaster, C Stewart, D R Rosenberg.   

Abstract

Neurobiological models for obsessive-compulsive disorder (OCD) have consistently implicated the caudate nucleus in the pathophysiology of this disorder. OCD symptoms improved markedly in a 9-year-old boy treated with paroxetine, a selective serotonin reuptake inhibitor, for whom pre/posttreatment proton magnetic resonance spectroscopic examinations were acquired to assess the relationship between neurochemical profile in the caudate nucleus, symptom severity, and treatment with paroxetine. Striking changes of the glutamate resonance in the caudate were observed after 12 weeks of paroxetine treatment. These data provide further support for glutamatergic-serotonin pathway involvement in the caudate nucleus of OCD patients.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9628087     DOI: 10.1097/00004583-199806000-00017

Source DB:  PubMed          Journal:  J Am Acad Child Adolesc Psychiatry        ISSN: 0890-8567            Impact factor:   8.829


  13 in total

1.  MRSI correlates of cognitive-behavioral therapy in pediatric obsessive-compulsive disorder.

Authors:  Joseph O'Neill; John C Piacentini; Susanna Chang; Jennifer G Levitt; Michelle Rozenman; Lindsey Bergman; Noriko Salamon; Jeffry R Alger; James T McCracken
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2011-10-01       Impact factor: 5.067

2.  Caudate volume differences among treatment responders, non-responders and controls in children with obsessive-compulsive disorder.

Authors:  Edoardo F Q Vattimo; Vivian B Barros; Guaraci Requena; João R Sato; Daniel Fatori; Euripedes C Miguel; Roseli G Shavitt; Marcelo Q Hoexter; Marcelo C Batistuzzo
Journal:  Eur Child Adolesc Psychiatry       Date:  2019-04-10       Impact factor: 4.785

Review 3.  Rodent models of obsessive compulsive disorder: Evaluating validity to interpret emerging neurobiology.

Authors:  Isaac Zike; Tim Xu; Natalie Hong; Jeremy Veenstra-VanderWeele
Journal:  Neuroscience       Date:  2016-09-16       Impact factor: 3.590

4.  Effects of intensive cognitive-behavioral therapy on cingulate neurochemistry in obsessive-compulsive disorder.

Authors:  Joseph O'Neill; Eda Gorbis; Jamie D Feusner; Jenny C Yip; Susanna Chang; Karron M Maidment; Jennifer G Levitt; Noriko Salamon; John M Ringman; Sanjaya Saxena
Journal:  J Psychiatr Res       Date:  2013-01-04       Impact factor: 4.791

Review 5.  Glutamate abnormalities in obsessive compulsive disorder: neurobiology, pathophysiology, and treatment.

Authors:  Christopher Pittenger; Michael H Bloch; Kyle Williams
Journal:  Pharmacol Ther       Date:  2011-09-22       Impact factor: 12.310

Review 6.  The cognitive-affective neuroscience of obsessive-compulsive disorder.

Authors:  D J Stein; W K Goodman; S L Rauch
Journal:  Curr Psychiatry Rep       Date:  2000-08       Impact factor: 5.285

Review 7.  Brain imaging in pediatric obsessive-compulsive disorder.

Authors:  Frank P MacMaster; Joseph O'Neill; David R Rosenberg
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2008-11       Impact factor: 8.829

Review 8.  Anxiety and affective disorder comorbidity related to serotonin and other neurotransmitter systems: obsessive-compulsive disorder as an example of overlapping clinical and genetic heterogeneity.

Authors:  Dennis L Murphy; Pablo R Moya; Meredith A Fox; Liza M Rubenstein; Jens R Wendland; Kiara R Timpano
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2013-02-25       Impact factor: 6.237

Review 9.  Glutamate-modulating drugs as novel pharmacotherapeutic agents in the treatment of obsessive-compulsive disorder.

Authors:  Christopher Pittenger; John H Krystal; Vladimir Coric
Journal:  NeuroRx       Date:  2006-01

Review 10.  A critical review of magnetic resonance spectroscopy studies of obsessive-compulsive disorder.

Authors:  Brian P Brennan; Scott L Rauch; J Eric Jensen; Harrison G Pope
Journal:  Biol Psychiatry       Date:  2012-07-24       Impact factor: 13.382

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.